NBIX Neurocrine Biosciences Inc.

78.43
-2.71  -3%
Previous Close 81.14
Open 81.37
Price To Book 14.83
Market Cap 7158029870
Shares 91,266,478
Volume 864,258
Short Ratio
Av. Daily Volume 777,958

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation 2Q/3Q 2019.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - children
Phase 2a positive interim data released March 12, 2019.
NBI-74788
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
INGREZZA
Tardive dyskinesia
NDA filing planned for 2Q 2019.
Opicapone
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
NDA filing due 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 data due late-2019.
INGREZZA - T-Force PLATINUM
Tourette syndrome - pediatric

Latest News

  1. Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company?
  2. See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
  3. Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
  4. Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences — Renewed Outlook, Key Drivers of Growth
  5. Analysts Raise Neurocrine Biosciences’ Target Price in March
  6. Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
  7. 2 Biotech Takeout Targets Perfect for Biogen
  8. Sage Stock Pops on FDA Approval for Postpartum Depression Drug
  9. CTLT or NBIX: Which Is the Better Value Stock Right Now?
  10. Neurocrine Biosciences Reports Positive Interim Results from Phase II Study of NBI-74788 in Adults with Classic Congenital Adrenal Hyperplasia
  11. Stocks Slide for Third Straight Day
  12. Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
  13. Why These 2 Biotech Stocks Might Be Next On The Takeover List
  14. Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Is An Attractive Investment To Consider
  15. Voyager Therapeutics stock jumps on 2nd Parkinson's deal
  16. Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT
  17. CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?